Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

Summary

This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment).

Timeline

Start

2013-04

Primary completion

2015-01

Completion

2015-01

Drugs

Indications